



US006174890B1

(12) United States Patent
Riga et al.**(10) Patent No.: US 6,174,890 B1**
(45) Date of Patent: Jan. 16, 2001**(54) ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF****(76) Inventors:** **Dan Riga; Sorin Riga**, both of Sector 1, Belgrade Street 7, Bucharest (RO), R-71248**(*) Notice:** Under 35 U.S.C. 154(b), the term of this patent shall be extended for 0 days.**(21) Appl. No.:** **08/750,159****(22) PCT Filed:** **Jun. 2, 1994****(86) PCT No.:** **PCT/RO94/00003**§ 371 Date: **Feb. 28, 1997**§ 102(e) Date: **Feb. 28, 1997****(87) PCT Pub. No.:** **WO95/33486**PCT Pub. Date: **Dec. 14, 1995****(51) Int. Cl.⁷** **A61K 645/06****(52) U.S. Cl.** **514/270; 514/276; 514/904; 514/905****(58) Field of Search** **514/276, 270, 514/904, 905****(56) References Cited****U.S. PATENT DOCUMENTS**

3,493,659 2/1970 Magid .

OTHER PUBLICATIONS

Stress and Psychiatry, Wilder, et al.; pp. 1198–1203; Comprehensive Textbook of Psychiatry/IV, vol. 1; Williams and Wilkins, Baltimore, 1985.

Neurobiology of Aging; Terry et al.; Aging, vol. 3; Raven Press, New York, 1976.

Subcellular genesis of the nerve lipofuscin pigments; Riga, et al.; Acta Anatomica, vol. 99, No. 3, 1977.

Executive stress goes global; Cooper, et al.; International Management, vol. 39, No. 5, pp. 42–48; May 1984.

Benzodiazepines—The Opium of the Masses?; M. Lader; pp. 609–615; Commentaries in the Neurosciences, Pergamon Press, Oxford, 1980.

Prevention of Mental, Psychosocial and Neurological Disorders in the European Region; W.H.O. Europe, 38th Session, Copenhagen, Sep. 1988.

The Effects of Caffeine; I.B. Syed; Journal of the American Pharmaceutical Association, vol. NS 16, pp. 568–572, Oct. 1976.

Handbook of Psychopharmacology; Iversen, et al.; vol. 11 Stimulants; Plenum Press, New York, 1978.

Changes in Lipofuscin pigments of rat . . . ; Riga, et al.; 9th International Congress of Gerontology, vol. 3, abstract No. 1103, p. 383, Kiev, USSR 1972.

Age-Associated Changes in the Hypothalamus of the Guinea Pig: Effect of Dimethylaminoethyl p-chlorophenoxyacetate. An Electron Microscope and Histochemical Study; M. Hasan, et al.; Exp. Geront., vol. 9, p. 153–159, 1974.

Effects of Centrophenoxine of the Lipofuscin Pigments in the Nervous System of Old Rats; Riga, et al.; Brain Research, 72(1974), p. 265–275.

Dynamics of lipofuscin pigments—directing factor of brain aging; Riga, et al.; p. 70; VI^e Congres Medical International, Prague, 1976.

An Attempt to Answer the Questions of Theoretical Gerontology on the Basis of the Membrane Hypothesis of Aging; Nagy; Advances in the Biosciences, vol. 64; 1987, p. 393–413.

Selected Histochemical and Histopathological Methods; Thompson, et al.; p. 1201–1234, 1305–1326; 1966.

Methodology of lipofuscin pigment research in neuroanatomy; Riga, et al.; Israel Journal of Medical Sciences, vol. 14, No. 8, p. 903, 1978.

Intracellular Localization of Lipofuscin Age Pigments in the Nervous System; Samorajski, et al.; Journal of Gerontology, vol. 19, p. 262–276, Jul., 1964.

Fine Structural Changes in the Lateral Vestibular Nucleus of Aging Rats; Johnson, et al.; Mechanics of Aging and Development, vol. 3, p. 203–224, 1974.

Clinical, Morphologic, and Neurochemical Aspects in the Aging Central Nervous System; Brody, et al.; Aging, vol. 1, New York, 1975.

The Deposition of Aging Pigment in the Human Cerebral Cortex; Brody; Journal of Gerontology, vol. 15, Jul. 1960, p. 258–261.

Macromolecular synthesis in developing and aging brain; Condorelli, et al.; Macromolecules in the Functioning Cell; p. 243–257, 1988.

Antagonic-Stress, Anew Treatment in Gerontopsychiatry and for a Healthy Productive Life; Predescu, et al.; p. 315–331; Pharmacology of Aging Processes, vol. 717, 1994.

Primary Examiner—Keith D. MacMillan*(74) Attorney, Agent, or Firm*—Cohen, Pontani, Lieberman & Pavane**(57)****ABSTRACT**

The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for its manufacturing. The drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent pathology. The drug achieves a synergistic biological, neurometabolic and cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress; methionine with aminoethanol phenoxyacetates and/or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxypyrimidine carboxylates and/or oxopyrrolidine acetamides with potassium, zinc and lithium; c) vasodilative and normolipidemic; nicotinic, alcohol and/or acid, or its derivatives, with magnesium and iodine; d) ergo-active and e) anti-toxic; aspartate; fructose; vitamin B₁; vitamin B₆; monoacid phosphate and sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or coated tablets, gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.

9 Claims, 9 Drawing Sheets